Insight

Aug 19, 2024, 06:27

New research reveals why EGFR+ lung cancer treatments may fail over time – EGFR Positive UK

EGFR Positive UK shared a post on X about a recent paper by Claire Lailler et al. published in Oncogene.

“PrPC controls epithelial-to-mesenchymal transition in EGFR-mutated NSCLC: implications for TKI resistance and patient follow-up”

Authors: Claire Lailler, Audrey Didelot, Simon Garinet, Hélène Blons, Sophie Mouillet-Richard et al.

New research reveals why EGFR+ lung cancer treatments may fail over time - EGFR Positive UK

“New research reveals why EGFR+ lung cancer treatments may fail over time: PrPC appears to play a crucial role in why some treatments stop working, potentially pointing the way to strategies to keep treatments effective longer and improve outcomes.”

Source: EGFR Positive UK/X

Audrey Didelot cancer Claire Lailler EGFR lung cancer EGFR Positive UK Hélène Blons Lung cancer OncoDaily oncogene Oncology Simon Garinet Sophie Mouillet-Richard

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage